NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, MBio Diagnostics said it is offering for sale $2.3 million of stock and warrant units.

The units consist of 10,000 shares of Series B-2 preferred stock and 10,000 warrants to purchase Series B-2 preferred stock. The company noted it has already raised $562,500, and plans to raise $1.7 million more.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.